Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

BACKGROUND: In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types are lacking. Data on how different scoring methods compar...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res
Autors principals: Guo, Hua, Ding, Qingqing, Gong, Yun, Gilcrease, Michael Z., Zhao, Min, Zhao, Jun, Sui, Dawen, Wu, Yun, Chen, Hui, Liu, Hui, Zhang, Jinxia, Resetkova, Erika, Moulder, Stacy L., Wang, Wei-Lien, Huo, Lei
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310491/
https://ncbi.nlm.nih.gov/pubmed/32576238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01303-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars